Reference | Study population; year of data collection; province(s) | Sample size | Mean age (SD) or age range | Method of detection | # cases‡ | HPV types detected | Overall HPV prevalence (any type)†| HR HPV prevalence | Methodological quality components |
---|---|---|---|---|---|---|---|---|---|
Peng 1988 [30] | Patients with abnormal pap smears Dates NR Ontario | 200 | NR | In-situ hybridization | 28 (HR16, 18) | Specific HPV types probed§ | NA | 14% (HR16, 18) | 1.N, 2.Y, 3.U, 4.N, 5.Y, 6.N, 7.Y |
Caussy 1990 [42] | Cases with cervical cancer, controls with CIN without cervical cancer 1960-1986 British Columbia | 141 | 35.6 (24) | In-situ hybridization | 31 | HR-16, 18 | 22% | 17.0% | 1.N, 2.Y, 3.U, 4.Y, 5.N, 6.N, 7.Y |
Duggan 1990 [29] | Patients referred to colposcopy clinic Dates NR Alberta | 119 | NR | Dot blot hybridization | 28 (HPV 16/18/33) | HR-16, 18, 33 LR-6, 11 | NA | 23.5% (HPV 16/18/33) | 1.N, 2.Y, 3.U, 4.N, 5.Y, 6.N, 7.U |
Rohan 1991 [60] | University Students: Routine Screening 1990 Ontario | 105 | 23 (median age) | PCR (E7/E6) | 19 | HR-16, 18, 33 LR-6, 11 | 12.3% | 10.5% | 1.Y, 2.Y, 3.Y, 4.N, 5.Y, 6.Y, 7.Y |
Guijon 1993 [47] | Patients referred to colposcopy clinic 1985-1990 Manitoba | 409 | 25.7 (NR) | In-situ hybridization | 280 | HR-16, 18, 33 LR-6, 11 | NA | 68.5% (HPV 16/18) | 1.N, 2.Y, 3.Y, 4.N, 5.Y, 6.N, 7.Y |
Brisson 1994 [41] | Patients referred to colposcopy clinic 1988-1989 Quebec | 1140 | Â | Southern Blot | 28.2 (6.6) | HR-16, 18 LR-6, 11 | NA | 24.3% (HPV-16) | 1.N, 2.Y, 3.Y, 4.N, 5.Y, 6.N, 7.Y |
Bosch 1995 [38] | Tumor biopsies of invasive cervical cancer 1989-1992 Province NR | 46 | NR | PCR (MY09/ MY11) | 43 | HR-16 | 93.5% | 91.3% | 1.NA, 2.Y, 3.NA, 4.N, 5.N, 6.Y, 7.Y |
Duggan 1995 [43]* | Cervical cancer tumour biopsies 1970-1990 Alberta | 76 | 47.3 (16.7) | Dot blot supplemented by PCR | 53 | All | 70.0% | 65.8% | 1.NA, 2.Y, 3.NA 4.Y, 5.N, 6.Y, 7.Y |
Franco 1996 [46] | Cervical cancer tumour biopsies 1983-1990 Quebec | 69 | NR | PCR (GP5+/GP6+) | 59 | HR-16, 18, 31, 33, 35 LR-6, 11 | 85.5% | 40.6% (HPV 16/18) | 1.NA, 2.Y, 3.NA, 4.N, 5.N, 6.Y, 7.Y |
Young 1997 [62] | General Public (Low-income, inner-city area): Routine Screening 1992-1995 Manitoba | 1263 | 73% less than 30 years | PCR (MY09/ MY11) | 411 | HR-16, 18, 31 LR-6, 11 | 32.5% | 18.0% (HPV 16/18) | 1.N, 2.Y, 3.U, 4.N, 5.Y, 6.Y, 7.Y |
Duggan 1997 [44]* | Cervical biopsies NR Alberta | 525 | 28.0 | PCR | 249 | HR-16, 18, 31, 33, 35 LR-6, 11 | 47.4% | 28.0% (HPV 16/18) | 1.N, 2.Y, 3.U, 4.Y, 5.Y, 6.Y, 7. U |
Michael 1999 [55] | University Students: Routine Screening NR Ontario | 99 | NR | PCR (MY09/ MY11) | 40 | HR-16, 18, 31, 33, 35 LR-6, 11 | 40.4% | 10.1% (HPV 16/18) | 1.N, 2.Y, 3.Y, 4.Y, 5.Y, 6.Y, 7.Y |
HIV positive 1993-2000 Multiple provinces | 375 | 32.5 | PCR (MY09/ MY11) | 252 | HR-16, 18 | 67.2% | 49.1% | 1.N, 2.Y, 3.U, 4.Y, 5.Y, 6.Y, 7.Y | |
Richardson 2000 [58] | University Students: Routine Screening 1992-1993 Quebec | 375 | 18-24 | PCR (MY09/ MY11) | 85 | HR- [11] LR-6,11,53 | 22.7% | 11.8% | 1.N, 2.Y, 3.Y, 4.N, 5.Y, 6.Y, 7.U |
Sellors 2000a [31]* | General Public: Routine Screening 1998-1999 Ontario | 955 (HC-II); 824 (PCR) | 15-49 | PCR (MY09/ MY11; HC-II | 110 | HR- [11] LR- [16] | 13.3% | 12.7% (HC-II) | 1.Y, 2.Y, 3.Y, 4.Y, 5.Y, 6.Y, 7.Y |
Sellors 2000b [35] | Patients recalled after an Abnormal Pap on Routine Screening 1996-1997 Ontario | 200 | 31.5 (9.4) | HC-II/PCR (L1) | 125 | HR- [13] LR-6,11,42,53 | 62.5% | 90.3% HSIL | 1.N, 2.Y, 3.Y, 4.N, 5.Y, 6.Y, 7.Y |
Ratnam 2000 [57] | General Public: Routine Screening 1996-1998 Newfoundland | 2098 | 30 (NR) | HC-I/HC-II | 227 (HR13) | HR- [13] LR-6,11,42,53 | NA | 10.8% | 1.Y, 2.Y, 3.Y, 4.Y, 5.Y, 6.Y, 7.Y |
Feoli-Fonseca 2001 [45]* [77] | Biopsies suspected of HPV Dates NR Quebec | 691 | 26.1 | PCR (MY09/ MY11/GP5+/GP6+) | 484 | HR- [13] | 70.0% | 92.0% (CIN III) 100% (carcinoma in situ) | 1.NA, 2.Y, 3.NA, 4.Y, 5.N, 6.Y, 7.Y |
Healey 2001 [50]* | General Public (Inuit): Routine Screening 1999 Nunavut | 1290 | 13-79 | HC-II | 333 | HR- [13] | Â | 25.8% | 1.Y, 2.Y, 3.Y, 4.Y, 5.Y, 6.Y, 7.Y |
Tran-Thanh 2002 [61]* [80] | Cases with SIL or invasive cancer and controls with normal cytology and no history of cervical disease 1998-2000 Quebec | 320 | 16-73 | PCR (MY09/ MY11) | 206 | HR- [13] | 64.4% | Â | 1.N, 2.Y, 3.Y, 4.N, 5.Y, 6.Y, 7.Y |
Sellors 2002 [32] | General Public: Routine Screening 1999-2000 Ontario | 156 | 50 and over | HCII/PCR | 13 | HR- [13] LR- [14] | NA | 8.3% (HC-II) | 1.N, 2.Y, 3.N, 4.N, 5.Y, 6.Y, 7.U |
Richardson 2003 [59]* [81] | University Students: Routine Screening 1996-1998 Quebec | 621 | 83% under age 27 years; mean age 23 (NR) | PCR (MY09/ MY11) | 180 | HR- [13] | 29% | 21.8% | 1.N, 2.Y, 3.U, 4.N, 5.Y, 6.Y, 7.Y |
Lytwyn 2003 [75]* [53] | Patients recalled after an Abnormal Pap: ASCUS or LSIL only 1995-1998 Ontario | 105 | 30.3 (8.1) | HC-II | 57 (HR13) | HR- [13] LR- [14] | NA | 54.3% | 1.Y, 2.Y, 3.Y, 4.Y, 5.Y, 6.Y, 7.Y |
Koushik 2005 [52]* | General Public: Cases with CIN from colposcopy clinics, controls with normal pap from screening. 2001-2003 Quebec | 357 cases, 760 controls | 32.0 (9.1) Cases, 31.7 (10.0) Controls | PCR (MY09/ MY11) | 579 | HR- [13] | 51.8% | 41.8% | 1.N, 2.Y, 3.Y, 4.Y, 5.Y, 6.Y, 7.Y |
Mayrand 2006 [54] | General Public: Routine Screening 2002-2004 Quebec, Newfoundland | 9620 | NR | HCII | 591 | HR- [13] LR- [24] | NA | 6.1% | 1.N, 2.Y, 3.Y, 4.Y, 5.Y, 6.Y, 7.Y |
Ogilvie 2007 [56] | Sex trade workers or women with a history of alcohol or drug abuse 2004-2005 British Columbia | 151 | 39.0 | HC-II | 43 (HC13) | HR- [13] | NA | 28.5% | 1.N, 2.Y, 3.Y, 4.N, 5.Y, 6.Y, 7.Y |
Kapala 2007 [51] | General Public: Routine Screening Date NR Ontario | 320 | 73% age 30 or greater | HC-II | 92 (HR13) | HR- [13] | NA | 28.8% | 1.NA, 2.Y, 3.NA, 4.N, 5.Y, 6.Y, 7.U |
Antionishyn 2008 [40] | Cervical biopsies 1995-1998 Saskatchewan | 1355 | NR | PCR (GP5+/GP6+) | 753 | HR- [13] | 55.6% | 56.8% CIN III (16 and 18) | 1.NA, 2.Y, 3.NA, 4.N, 5.Y, 6.Y, 7.Y |
Hamlin-Douglas 2008 [48] | General Public (Inuit): Routine Screening 2002-2007 Quebec | 554 | 35.5 (14.4) | PCR (MY09/ MY11) | 160 | All | 28.9% | 20.4% | 1.Y, 2.Y, 3.N, 4.Y, 5.Y, 6.Y, 7.Y |
Moore 2009 [39] | Population-based estimates weighted by cytology 2004 British Columbia | 4821 | 13-86 | PCR (GP5+/GP6+) | 810 | All | 16.8% | 13.9% | 1.NA, 2.Y, 3.NA, 4.Y, 5.Y, 6.Y, 7.N |